ESR1 and breast carcinoma: On the other hand, PRMT2 methyltransferase itself was shown to improve the sensitivity of tamoxifen in ER positive breast cancer cells by transcriptionally suppressing the 36 kDa variant of estrogen receptor a, ER-a36 [147].